Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
36.53
-0.19 (-0.52%)
At close: Feb 13, 2026, 4:00 PM EST
36.75
+0.22 (0.60%)
After-hours: Feb 13, 2026, 7:59 PM EST
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
205
Market Cap
5.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 7.87M | -14.63M | -65.02% |
| Dec 31, 2019 | 22.50M | 12.77M | 131.14% |
| Dec 31, 2018 | 9.73M | 1.37M | 16.44% |
| Dec 31, 2017 | 8.36M | 2.01M | 31.55% |
| Dec 31, 2016 | 6.36M | 3.37M | 112.83% |
| Dec 31, 2015 | 2.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.78B |
| Caris Life Sciences | 649.06M |
| Mirum Pharmaceuticals | 471.79M |
| Protagonist Therapeutics | 209.22M |
| Rhythm Pharmaceuticals | 174.33M |
| ImmunityBio | 82.56M |
| CRISPR Therapeutics AG | 3.51M |
COGT News
- 4 days ago - Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting - GlobeNewsWire
- 19 days ago - Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) - GlobeNewsWire
- 23 days ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 25 days ago - Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) - GlobeNewsWire
- 4 weeks ago - Cogent Biosciences, Inc. (COGT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio - GlobeNewsWire
- 5 weeks ago - Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day. - Barrons